Innovations in Alzheimer’s disease therapy and understanding are mounting. The FDA recently approved injectable Leqembi by Eisai and Biogen facilitating home-based weekly maintenance dosing, expanding patient convenience and adherence potential. Research reveals estrogen receptor beta (ERβ) confers gender-specific neuroprotection in murine Alzheimer models. Separately, studies detail altered brain signaling distinguishing Parkinson’s disease from essential tremor, shedding light on differential neurodegenerative mechanisms. Collectively, these findings contribute to personalized and accessible dementia care strategies.